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Platelet-Bacterial Interactions as  
Therapeutic Targets in Infective Endocarditis 
Steven W. Kerrigan and Dermot Cox 
Royal College of Surgeons in Ireland 
Dublin,  
Ireland 
1. Introduction 
Endocarditis is an inflammation of the lining of the heart and valves. It can be due to a non-
infectious cause (Asopa et al., 2007) but when the inflammation is associated with an 
infection, usually bacterial, it is known as infective endocarditis (IE) and is characterized by 
the development of a large septic thrombus on one of the cardiac valves (Beynon et al., 2006; 
Moreillon and Que, 2004). As this thrombus grows, it can lead to valve failure or may 
fragment forming a septic embolus that is associated with high mortality if the target of the 
embolus is the brain, heart or lung (Homma and Grahame-Clarke, 2003). Untreated the 
mortality is very high and even with aggressive therapy with antibiotics and valve 
replacement surgery there is a significant mortality. Primarily the disease is due to the 
formation of a platelet-bacteria thrombus on a cardiac valve and this review will look at the 
interaction between bacteria and platelets within the context of endocarditis.  
2. Traditional role of platelets in thrombosis 
Platelets are anucleate fragments of megakaryocytes and their primary role is in 
haemostasis. Damage to the endothelium surrounding blood vessels leads to the exposure 
of the sub-endothelial layer that is rich in collagen and immobilised plasma proteins such as 
von Willebrand factor (vWf). Platelets bind to the newly exposed collagen and become 
activated. Many blood vessels, such as the coronary arteries are high shear vessels and the 
blood is flowing too fast to allow the platelets to bind to the collagen. However, under these 
high shear conditions immobilised vWf can interact with platelet GPIb, which slows down 
the platelets allowing them to subsequently interact with collagen. Once activated platelets 
aggregate to form a thrombus which the damaged blood vessel. GPIIb/IIIa mediates platelet 
aggregation by binding plasma fibrinogen, which as a divalent protein can bind to two 
separate GPIIb/IIIa molecules. As a result, activated platelets are cross-linked by fibrinogen, 
which forms the aggregates that seal the damaged vessel.  
Platelets are highly responsive and can be activated by many different agonists. As well as 
two different collagen receptors (α2β1 and GPVI) and two ADP receptors P2X1 and P2Y12, a 
serotonin receptor, an adrenergic receptor and a thromboxane A2 receptor there are also 
three thrombin receptors (Protease-activated receptor (PAR)-1, GPIbα and PAR-4). Platelet 
 
Endocarditis 
 
52 
activation is dependent on the sum of the signals from all of these receptors and not on any 
specific receptor. Signalling from these receptors is either phospholipase A2/cyclooxygenase 
(COX)-mediated, resulting in the generation of thromboxane A2, or protein kinase C-
mediated. In contrast, the generation of intracellular cAmp in response to prostacylin 
binding to its receptor acts to inhibit platelet activation.  
Aside from their ability to adhere to sites of damage and to form aggregates, platelets also 
secrete their granule contents in response to activation. Platelets contain three different 
granules: α-granules, dense granules and lysosomes. Dense granules are rich in small 
molecules especially ATP/ADP and serotonin, α-granules contain numerous plasma 
proteins typically associated with haemostasis and the lysosomes contain acid hydrolases. 
These secreted products act to enhance haemostasis as ADP activates other platelets, 
serotonin causes vasoconstriction and the secreted proteins support platelet aggregation. 
3. The role of platelets in innate immunity 
The biological role of platelets is not confined to haemostasis as platelets also play an 
important role in the innate immune system (Cox et al., 2011; Semple and Freedman, 2010). 
Platelets are ideally suited to this as they are present at very high concentration in the blood 
and are the first responders to any damage to the vasculature, which is the primary 
mechanism by which pathogens gain entry to the blood. To facilitate this, platelets contain 
surface receptors that allow it to respond to pathogens. Platelets contain pattern recognition 
receptors, especially Toll-like receptors (TLRs). These and other receptors (see below) allow 
platelets to respond to pathogens. As with other platelet agonists, platelets respond to 
pathogens by adhering to them and subsequently become activated leading to thrombus 
formation and secretion. In the context of the innate immune system, secretion is the 
primary response. Activated platelets secrete anti-microbial peptides that act to kill bacteria 
(Mercier et al., 2004). They also secrete cytokines such as CD40L and RANTES (Antczak et 
al., 2010) that act to recruit and activate a variety of immune cells to deal with the invading 
microorganism. Thus, platelets play a key role in the innate immune system where they 
directly act to kill bacteria as well as coordinating the response of the immune system to the 
pathogens.  
4. The role of platelets in infective endocarditis 
IE arises when the bacteria subvert the platelet response to infection and as a result, platelets 
become part of the pathogenic process. In IE the platelets interact with the bacteria and 
become activated. They secrete anti-microbial peptides but the bacteria are resistant. Once 
activated the platelets aggregate resulting in the formation of a platelet-bacteria aggregate. 
Not only are the bacteria resistant to the anti-bacterial peptides (Bayer et al., 1998; Fowler et 
al., 2000), they become surrounded by platelets and are able to evade immune surveillance. 
To further complicate matters even if the bacteria are susceptible to antibiotics, many 
antibiotics have poor penetration into the thrombus despite adequate plasma levels making 
treatment more difficult. 
While the list of pathogens that have been known to cause IE is long (Baddour et al., 2005), 
the vast majority of cases with an identified pathogen are due to Staphylococci (primarily S. 
aureus) or Streptococci (primarily S. sanguinis and S. oralis). However, around 25% of IE cases 
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are culture negative with no bacteria isolated from the blood (Naber and Erbel, 2007). There 
are a number of reasons for the failure to culture any organisms such as commencement of 
antibiotic therapy prior to obtaining the blood sample, infection with a fastidious bacterium 
or a non-bacterial (e.g., fungal) endocarditis. In this review we will focus on the mechanism 
of platelet activation by Staphylococci and Streptococci as not only are they the dominant 
species involved in IE but they are also the best studied. While even different strains of a 
bacterial species differ in their ability to interact with platelets some general principles can 
be seen which is important in devising new treatment strategies. 
5. Platelet-bacterial interactions: General observations 
There are three different types of interaction between platelets and bacteria. The first is an 
inherent ability of platelet receptors to recognise bacterial surface components. 
Alternatively, plasma proteins can bind to bacteria and these proteins can in turn bind to a 
platelet receptor. Typically these are acute phase reactants such as fibrinogen and 
complement. A third mechanism for interacting with platelets is the secretion of bacterial 
products or toxins that interact with platelets. The binding of platelets to bacteria either 
through a direct interaction or via a bridging protein can mediate platelet adhesion and/or 
platelet activation. Interactions with bacterial toxins leads to either platelet lysis or platelet 
activation. Typically bacterial proteins that mediate adhesion are distinct from those that 
mediate aggregation. Thus, bacteria can support platelet adhesion and/or trigger platelet 
activation. During sepsis the primary interaction between platelets and bacteria is platelet 
activation and is mediated by both toxin secretion and a direct interaction with the bacteria. 
However, infective endocarditis is a focal infection of a damaged heart valve. The initial step 
is mediated by adhesion to the damaged valve as well as subsequent adhesion of platelets to 
the immobilised bacteria. This adhesive interaction is important in ensuring that the bacteria 
and thrombus remain attached to the valve despite the presence of turbulent flow 
conditions. For IE to develop the initial adhesive interaction must be followed by activation 
of the platelets leading to platelet recruitment and growth of the thrombus. Most bacteria 
can interact with platelets through multiple mechanisms making it difficult to identify the 
roles of the different proteins (both bacterial and platelet) and is further complicated by 
interactions that are not only species-specific but strain-specific as well.  
6. Platelet-bacterial interactions: The Staphylococcus 
Regardless of the modern advances in antimicrobial therapy and surgical intervention 
Staphylococcus aureus is still the most frequent etiologic microorganism found in Infective 
endocarditis (Rasmussen et al., 2011). Its interaction with platelets is well characterised. 
Much of the investigations to date have focused on two separate but related features of this 
relationship; 1) toxins and 2) cell wall protein mediators of platelet activation (Table 1).  
S. aureus is known to secrete several extracellular toxins. Alpha (α)-toxin is a 34 kDa toxin 
composed of 293 amino acids (Bernheimer, 1965). It is produced by almost all strains of S. 
aureus. Its expression is accessory-gene regulon (agr)-regulated and is secreted into the 
extracellular environment as a monomeric water soluble protein (Ikigai and Nakae, 1985). 
The toxin disrupts the cell membranes by binding to the lipid bilayer, forming an 
oligomeric structure that forms a water filled transmembrane pore (Valeva et al., 1996). 
Studies have demonstrated that the toxin has primarily two modes of interaction with host 
 
Endocarditis 
 
54 
cells. These include binding specifically to the host target at low concentrations and non-
specific adsorption to host target cell membranes at higher concentrations (Hildebrand et 
al., 1991).  
Siegel and Cohen were the first to demonstrate that addition of α-toxin to human platelet-
rich plasma induced platelets to undergo shape change and aggregation (Siegel and Cohen, 
1964). In this study the authors demonstrated that platelets leaked their intracellular ions 
NAD+, K+ and ATP but not protein, into the surrounding environment thus concluding that 
the platelets were not being lysed. Additional studies demonstrated that when platelets 
were treated with α-toxin it caused them to swell but there were no clear signs of platelet 
lysis by electron microscopy (Bernheimer and Schwartz, 1965; Manohar et al., 1967). Further 
investigations into the molecular mechanism through which platelets became activated, 
found that pore formation gave rise to an increase in intracellular calcium concentration 
(Arvand et al., 1990; Baliakina et al., 1999). Arvand et al demonstrated that α-toxin triggers a 
platelet signal that leads to secretion of intracellular contents including procoagulant 
mediators, platelet factor 4 and factor V. Secreted factor V in turn associates with the platelet 
membrane leading to assembly of the prothrombinase complex (Arvand et al., 1990). This 
explains the major pathway responsible for the procoagulatory effects of α-toxin. Bayer et al. 
used 2 models to investigate the role of α-toxin on platelets. In the first and consistent with 
the above observations, the authors demonstrated that α-toxin caused platelet lysis which in 
turn caused the release of platelet microbial proteins (PMP’s). The release of PMPs from 
platelets was bactericidal to S. aureus. Using an animal model of endocarditis the authors 
demonstrated that different strains of S. aureus differed in the expression of functional 
versus mutant forms of α-toxin. Under these conditions, the S. aureus strains producing 
either minimal or no α-toxin were less virulent in vivo than wild-type strains (Bayer et al., 
1997). Wild-type S. aureus strains or indeed an isogenic strain engineered to over-express α-
toxin were associated with increased release of PMP from platelets. These results suggest 
that when S. aureus releases α-toxin in the vicinity of platelets it triggers them to release of 
PMP’s and therefore forging a protective role for the host by destroying the α-toxin 
producing S. aureus.  
Lipoteichoic acid (LTA) is a component of gram positive bacteria (Morath et al., 2005) and is 
often released from the bacteria upon lysis or after treatment with β-lactam antibiotics (Lotz 
et al., 2006). It also stimulates a strong immune response through an interaction with toll like 
receptors expressed on many host cells (Zahringer et al., 2008). Toll like receptor 2 (TLR2) 
recognises LTA and there are now many reports in the literature demonstrating that TLR2 is 
expressed and functional on platelets (Blair et al., 2009; Keane et al., 2010b; Kerrigan et al., 
2008; Ward et al., 2005) suggesting that platelets can respond to LTA. Early reports 
demonstrated that S. aureus LTA inhibits platelet activation by activating the cyclic AMP 
pathway (Sheu et al., 2000a; Sheu et al., 2000b).  
S. aureus predominantly uses multiple cell wall surface proteins to interact with platelets to 
trigger their activation. Early studies by Hawiger et al. demonstrated that S. aureus cell wall 
protein A acts as a receptor for specific anti-staphylococcal antibodies which in turn bind 
FcγRIIa on platelets (Hawiger et al., 1979). This interaction triggers an intracellular signal 
that leads to granule release and platelet aggregation. While this interaction is important, 
deletion of protein A failed to abolish S. aureus binding to platelets. This observation 
suggests that other interactions between S. aureus and platelets exist.  
 
Platelet-Bacterial Interactions as Therapeutic Targets in Infective Endocarditis 
 
55 
Clumping factor A (ClfA) is a 97kDa protein has been shown to bind plasma fibrinogen. A 
mutant of S. aureus lacking clumping factor A (ClfA) failed to adhere to platelets, suggesting 
that ClfA binds fibrinogen which in turn binds the platelet fibrinogen receptor, GPIIbIIIa 
(Sullam et al., 1996). Further characterisation of this interaction suggested that ClfA also 
requires IgG in order to trigger platelet aggregation. Addition of fibrinogen and ClfA-
specific immunoglobulin to the plasma-free system led to S. aureus-induced platelet 
aggregation. Even though resting GPIIbIIIa has little or no affinity for soluble fibrinogen it 
can still bind fibrinogen bound to bacteria, however this is not enough to trigger activation. 
To trigger full platelet activation both fibrinogen and specific immunoglobulin must bind to 
the A domain on ClfA. There are two distinct sites on ClfA that allows fibrinogen and IgG 
binding at the same time (Loughman et al., 2005). Once bound fibrinogen molecules can 
engage resting GPIIbIIIa, aided by bound ClfA specific immunoglobulin, which encourages 
the clustering of Fc receptor, FcγRIIa. This triggers activation of signal transduction leading 
to conformational change in GPIIbIIIa and aggregation of platelets.  
Deletion of the fibrinogen binding domain (ClfA-PY) but not the IgG binding domain on 
ClfA led to the discovery of a second pathway S. aureus uses to induce platelet aggregation. 
By removing the fibrinogen binding domain in ClfA S. aureus induced platelet aggregation 
very slowly (between 8-20 minutes compared to 2-4 mins). These results suggest that IgG 
binding to ClfA alone is not enough to trigger platelet aggregation. Using a series of 
elimination experiments Loughman et al. demonstrated that complement must assemble on 
the S. aureus surface and then bind to unidentified complement receptors on the platelet. 
Therefore, in the absence of fibrinogen binding complement and specific immunoglobulin 
are required for platelet activation to occur (Loughman et al., 2005).  
A major limitation in our current understanding of platelet bacterial interactions stems 
from the fact that the majority of studies cited in the literature to date have been carried out 
under static conditions (static adhesion assays) or non-physiological stirring conditions 
(platelet aggregation). Therefore, data obtained using in vitro assays may not be relevant to 
the fluid shear environment that platelets encounter in the vasculature. Indeed many 
reports suggests that the local fluid environment of the circulation critically affects the 
molecular pathways of cell-cell interactions (Varki, 1994). All of the early S. aureus studies 
were carried out under static or non-physiological stirring conditions and therefore it is 
difficult to relate these studies to the disease processes. Studies using a cone and plate 
viscometer (a device that shears cells at a given flow rate) have demonstrated that protein 
A, ClfA, SdrC, SdrD and SdrE are important in thrombus formation (George et al., 2007; 
George et al., 2006; Pawar et al., 2004). However, extremely high shear rates were used in 
these rheological studies. Using another method of investigating the influence of shear 
rates on S. aureus ability to induce platelet activation, Kerrigan et al. perfused platelets over 
an immobilised monolayer of S. aureus in a parallel flow chamber. This method 
demonstrated that platelets perfused over S. aureus under shear conditions equivalent to 
arterial pressure led to very strong adhesion followed by rapid aggregate formation 
(Kerrigan et al., 2008). Deletion of ClfA from S. aureus, abolished adhesion and aggregate 
formation under all shear rates investigated. Using a plasma-free system, fibrinogen led to 
single platelet adhesion but not aggregate formation. Specific immunoglobulin failed to 
have any effect on either platelet adhesion or aggregation. However, addition of fibrinogen 
and specific immunoglobulin to the plasma-free system led to platelet adhesion followed 
by aggregate formation (Kerrigan et al., 2008) thus highlighting the importance of 
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fibrinogen and IgG in aggregate formation induced by S. aureus. No interaction was seen 
under low shear conditions using a parallel flow chamber.  
S. aureus have a wide array of proteins expressed on their surface. This protein expression 
profile is most likely part of their survival. For example, ClfA is expressed weakly at the 
exponential phase of growth whereas is expressed strongly at the stationary phase of 
growth. In contrast to this another major S. aureus protein, fibronectin binding protein A 
(FnBPA) is strongly expressed at the exponential phase of growth and weakly expressed at 
the stationary phase of growth.  
FnBPA is a 112kDa cell wall bound protein which binds plasma fibronectin and 
immunoglobulin. Fnbp contain a specific immunoglobulin binding domain (A domain) and 
a separate fibronectin binding domain (BCD). The FnBPA A domain is similar in structure 
and function to that of the ClfA A domain. FnBPA possesses two different but related 
mechanisms of engaging and activating platelets (Fitzgerald et al., 2006b). In the first 
mechanism, fibrinogen can bind to the A domain which crosslinks to GPIIb/IIIa, and 
specific immunoglobulin must crosslink to FcγRIIa to trigger platelet activation and 
aggregation (Fitzgerald et al., 2006b). In the second mechanism the fibronectin binding 
domain, BCD, can independently activate platelets. Fibronectin can bind to S. aureus via the 
FnBPA BCD domain by the tandem β-zipper mechanism (Meenan et al., 2007; Raibaud et al., 
2005; Schwarz et al., 2003) and also to platelet GPIIbIIIa through the common integrin 
recognition motif RGD (Fitzgerald et al., 2006b). The signal to trigger platelet 
activation/aggregation is complete when specific immunoglobulin binds the A domain of 
FnBPA and cross links to platelet FcγRIIa.  
Clumping factor B is a 98 kDa protein highly expressed on the surface of S. aureus during 
the exponential phase of growth and shares sequence homology with ClfA (McAleese et al., 
2001). Similar to ClfA, ClfB can also bind fibrinogen and specific immunoglobulin. Deletion 
of the fibrinogen binding site on ClfB led to a slower aggregation. Characterization of this 
slower response suggested that complement assembly was required along with 
immunoglobulin to trigger aggregation (Miajlovic et al., 2007). Therefore similar to S. aureus 
ClfA and FnBPA, ClfB is also capable of triggering platelet aggregation via 2 specific 
mechanisms; fibrinogen and immunoglobulin or complement and immunoglobulin. 
Although the complement receptor on platelets has not yet been definitively identified in 
these interactions, Nguyen et al. has demonstrated that S. aureus protein A is capable of 
binding to the complement receptor gC1qR/p33 (Nguyen et al., 2000). As gC1qR/p33 is 
only expressed on platelets upon activation rather than at resting, it suggests that the 
complement interaction may act as an anchor, as it this interaction occurs after the initial 
platelet activation response.  
Staphylococcal protein A (SpA) is a 55kDa protein expressed on greater than 90% of S. 
aureus strains. SpA is made up of 5 repeat domains (A-E) which have been shown to bind to 
the A1 domain of the major plasma protein vonWillebrand factor with high affinity (low nM 
range) (Hartleib et al., 2000; O'Seaghdha et al., 2006). Platelets express a high affinity 
vonWillebrand factor receptor called GPIbα (Andrews et al., 2003). Under very high shear 
conditions, Pawar and colleagues demonstrated that deletion of SpA from S. aureus 
significantly reduced its interaction with platelets (Pawar et al., 2004). Furthermore, 
preincubating platelet rich plasma with a vonWillebrand Factor antibody or indeed blocking 
the platelet GPIbα receptor with an inhibitory monoclonal antibody partially inhibited the 
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platelet-S. aureus interaction (Pawar et al., 2004). Thus highlighting the importance of this 
platelet specific receptor in recognising S. aureus. 
Bacteria Bacterial 
protein 
Platelet 
receptor 
Bridging 
protein 
Response  
     
Staphylococcus 
aureus 
α-toxin None None Aggregation 
 Lipoteichoic 
acid  
Not identified None Aggregation 
 Protein A FcγRIIa, 
gC1R/p33,  
GPIbα 
IgG, 
complement, 
vonWillebrand 
factor 
Aggregation / 
adhesion / 
thrombus 
formation 
 
 ClfA GPIIbIIIa, 
FcγRIIa, 
 
Fibrinogen, IgG 
& complement 
Aggregation / 
thrombus 
formation 
 SdrC Not identified Not identified Thrombus 
formation 
 SdrD Not identified Not identified Thrombus 
formation 
 SdrE Not identified Not identified Thrombus 
formation 
 FnbpA/B GPIIbIIIa, 
FcγRIIa 
Fibrinogen, IgG 
& complement 
Aggregation / 
thrombus 
formation 
 ClfB GPIIbIIIa, 
FcγRIIa 
Fibrinogen, IgG 
& complement 
 
 SraP Not identified None Thrombus 
formation 
 IsdB GPIIbIIIa None Aggregation / 
adhesion 
Table 1. List of molecular interactions between Staphylococci and platelets that contribute to 
Infective Endocarditis 
Serine rich protein SraP is a 227kDa large protein and a member of the highly conserved 
family of serine rich surface glycoproteins expressed on the cell wall of S. aureus (Siboo et 
al., 2005). A mutant strain of S. aureus lacking expression of SraP displayed signs of reduced 
virulence in a rabbit model of infective endocarditis, implicating its role in the development 
of a growing thrombus on a cardiac valve. The platelet receptor that SraP binds to is not 
currently known. SraP shares similarility with a group of cell wall-associated glycoproteins 
(Ramboarina et al., 2010) found in a number of other organisms including Streptococcus 
sanguinis (Plummer et al., 2005), Streptococcus gordonii (Kerrigan et al., 2007) both of which 
have been have been shown to bind to platelet GPIbα. Interestingly however, SraP does not 
seem to bind to GPIbα.  
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In vivo, S. aureus has restricted access to iron and as a result express iron regulated surface 
proteins to capture haem from haemogloblin and transport it into the cell (Skaar and 
Schneewind, 2004). Iron-regulated surface determinant B (IsdB) is a 70kDa family member 
that has been shown to bind to the platelet fibrinogen receptor GPIIbIIIa. S. aureus grown in 
iron limited conditions bound to platelets in a plasma free environment, suggesting that a 
plasma bridge bridge is not necessary for interacting with or inducing platelet activation. 
Mutants defective in the expression of IsdB were unable to adhere to or aggregate platelets. 
Using surface plasmon resonance Miajlovic et al demonstrated a direct interaction between 
purified GPIIbIIIa and recombinant IsdB (Miajlovic et al., 2010).  
In addition to S. aureus having the ability to interact with platelet either directly or indirectly 
Youssefian and colleagues reported that platelets were also capable of internalising S. aureus 
(Youssefian et al., 2002). While internalisation corresponded with platelet activation the 
mechanism through which this occurred is currently not known. Moreover it is also yet to 
be established whether the S. aureus is destroyed once internalised in a manner similar to 
phagocytosis by immune cells.  
7. Platelet-bacterial interactions: The Streptococcus 
Viridans streptococci are common commensals of the oral cavity, respiratory tract, and 
gastrointestinal mucosa. In their respective environment these microorganisms are harmless, 
however following trauma to the mucous membranes they can enter to the normally sterile 
environment of the bloodstream. Once inside the bloodstream the viridans streptococci act as 
pathogens (Baddour et al., 1989) and often colonise heart valves, causing infective endocarditis 
(Moreillon et al., 2002) or become implanted in atherosclerotic plaques, exacerbating 
atherosclerosis (Chiu, 1999) mainly through an interaction with platelets (Table 2).  
Streptococcus sanguinis is a common oral microorganism that is isolated from patients with 
infective endocarditis. In fact early studies demonstrated that 60% of S. sanguinis strains 
induced platelet aggregation in vitro (Herzberg and Meyer, 1996). Douglas et al provided 
strong evidence that there is a relationship between the virulence of the infecting S. sanguinis 
strains and their ability to aggregate platelets in vitro (Douglas et al., 1990). S. sanguinis 
induced platelet aggregation was largely found to be dependent on physiological 
concentrations of calcium and fibrinogen, and some strains required non-specific antibody. 
Platelet adhesion to S. sanguinis occurred independently of calcium, fibrinogen or non-
specific antibody, suggesting that platelet adhesion and platelet aggregation are mediated 
independently of each other (Kerrigan et al., 2002). These observations led to the early 
model of platelet bacterial interaction where a class I component mediated adhesion to the 
platelet, a class II component mediates a calcium dependent activation of the platelet and 
finally a class III component mediates a calcium and fibrinogen-dependent amplification of 
the response (Herzberg, 1996).  
The initial studies focused on identifying the class I and class II components. Treatment of S. 
sanguinis with L- (tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-trypsin liberated 
cell free peptides (Herzberg et al., 1983). Purification of these peptides failed to support 
platelet adhesion or trigger platelet aggregation, however, did inhibit S. sanguinis mediated 
platelet aggregation and adhesion. This studies concluded that that these TPCK-tryptic 
peptides contained antigenic determinants that recognise platelets thus preventing S. 
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sanguinis from binding. Using immunoaffinity chromatography and ion exchange 
chromatography, Erickson and colleagues identified a platelet aggregation-associated 
protein (PAAP) (Erickson and Herzberg, 1990). PAAP is synthesized as a 150 kDa 
glycoprotein which is 40% carbohydrate and is constitutively expressed on the surface of S. 
sanguinis (Erickson and Herzberg, 1993; Erickson et al., 1992). The peptide sequence pro-gly-
glu-gln-gly-pro-lys in the PAAP conforms to a predicted consensus motif common to the 
platelet interactive domain of collagen, lys-pro-gly-glu-pro-gly-pro-lys (Erickson and 
Herzberg, 1990). More recently Herzberg and colleagues identified a putative collagen-
binding protein containing 2 PAAP sequences (Herzberg et al., 2005). PAAP is 
environmentally controlled during infection in response to high temperature (fever) or 
exposed collagen (exposed on damaged blood vessels or damaged heart valves) (Heimdahl 
et al., 1990). Partial sequence alignment shows homology of PAAP to heat shock proteins of 
Mycobacterium tuberculosis and E. coli (Herzberg and Meyer, 1996). The platelet receptor for 
PAAP is currently unidentified.  
Ford et al demonstrated that S. sanguinis strain NCTC 7863 induced aggregation of normal 
platelets suspended in plasma however removal of plasma proteins abolished platelet 
aggregation (Ford et al., 1996). The long lag time (12-15mins) of S. sanguinis strain 7863 was 
progressively shortened by incubating the bacteria in plasma for increasing lengths of time 
prior to addition to platelets. This suggested that plasma proteins were essential for platelet 
aggregation. Subsequent experiments demonstrated that complement assembly on the 
surface of the bacteria was necessary for aggregation of platelets. Further experiments 
demonstrated that complement assembly was not enough to trigger platelet aggregation 
which led to the discovery that IgG and fibrinogen was necessary to complete the 
aggregation process (Ford et al., 1997). More recently McNicol and colleagues demonstrated 
that depletion of S. sanguinis-specific antibodies from plasma prevented platelet aggregation 
(McNicol et al., 2006). Following S. sanguinis binding, addition of antibodies led to rapid 
phosphorylation of the platelet antibody receptor, FcγRIIa (Pampolina and McNicol, 2005) 
and further downstream effector targets such as phospholipase Cγ2, syk and adapter 
molecule LAT.  
In 2002 Kerrigan et al, demonstrated that S. sanguinis strain 133-79 bound to the platelet 
vonWillebrand factor receptor, GPIbα (Kerrigan et al., 2002). There was no requirement for 
vonWillebrand factor or immunoglobulin binding in this system, suggesting that S. sanguinis 
binds directly to platelet GPIbα. Confirmation for the role of GPIbα was provided when a 
range of site-specific inhibitory monoclonal antibodies against GPIbα prevented S. sanguis 
binding to the platelet. In addition, enzymatic cleavage of GPIbα using the snake venom from 
a viper pit localised the binding region within the N-terminal 1-225 portion of GPIbα. Finally, 
platelets from patients with Bernard Soulier Syndrome (patients who fail to express GPIbα on 
the surface of their platelets) did not aggregate in response to S. sanguinis (Kerrigan et al., 
2002). The S. sanguinis protein that binds GPIbα was purified from cell wall extracts by 
chromatography on GPIbα and wheat germ agglutinin affinity matrices (Plummer et al., 2005). 
This led to the identification of a highly glycosylated serine-rich protein called serine-rich 
protein A (SrpA). An insertional inactivation mutant lacking the SrpA of S. sanguinis showed a 
significant increase in the lag time to aggregation, implicating this protein in platelet 
aggregation. In addition, platelet adhesion to the SrpA mutant was significantly reduced, 
however not abolished, suggesting other factors are involved in supporting platelet adhesion. 
 
Endocarditis 
 
60 
Streptococcus gordonii is a close but distinct relative of S. sanguinis (Nobbs et al., 2009), 
however initial reports suggested that S. gordonii could not induce platelet aggregation 
(Douglas et al., 1990). More in depth characterisation has demonstrated that S. gordonii is 
capable of supporting platelet adhesion and inducing platelets aggregation in a strain 
dependent manner. Glycosylated surface protein B is a large 280kDa protein expressed on 
the surface of S. gordonii strain M99. It is heavily glycosylated with glucose and glucosamine 
and is transported to the cell surface via an accessory system compromising of the SecA2 
and the SecY2 proteins (Bensing and Sullam, 2002; Takahashi et al., 2004). GspB has been 
shown to be highly homologous to an expanding family of Gram-positive bacterial cell 
surface proteins that includes S. aureus serine rich protein SraP (Siboo et al., 2005) S. sanguis 
serine-rich protein SrpA (Plummer et al., 2005), S. gordonii DL1 sialic acid-binding protein 
Hsa (Takahashi et al., 2002) and the S. parasanguinis fimbriae-associated protein Fap1 (Wu et 
al., 2007). These proteins were originally discovered because of their ability to bind a variety 
of sialylated glycoproteins. Platelet GPIbα is an example of a sialylated glycoprotein and as 
a result has been shown to bind S. gordonii GspB and Hsa (Bensing et al., 2004). Additional 
molecular glycan characterisation demonstrated that GspB specifically binds O-linked sialic 
acid residues on GPIbα (Takamatsu et al., 2005), whereas Hsa specifically binds N-linked 
sialic acid residues on GPIbα and GPIIbIIIa (Yajima et al., 2005). Interestingly an isogenic 
mutant lacking the expression of Hsa in S. gordonii strain DL1 failed to affect percent platelet 
aggregation however reduced platelet adhesion by ~ 50%. These more recent functional 
studies suggest that additional protein interactions are necessary for supporting platelet 
adhesion (Jakubovics et al., 2005a).  
S. gordonii expresses a large protein of ~3500 amino acids with a high molecular weight of 
397 kDa designated platelet adherence protein A (PadA) (Petersen et al., 2010). PadA 
contains a short stretch of amino acid residues which displays weak homology to A1 and C1 
domain of the plasma protein, vonWillebrand factor (vWf). These domains in vWf are 
essential for interactions with platelet GPIb and GPIIb/IIIa, respectively. Disruption of the 
PadA gene from S. gordonii DL1 failed to affect binding to glycocalacin (soluble purified 
GPIbα), however, ablated binding to purified GPIIb/IIIa. Furthermore, platelet adhesion to 
S. gordonii DL1 was significantly reduced by preincubation of platelets with an integrin 
recognition RGD-containing peptide or the GPIIb/IIIa inhibitor, abciximab (Petersen et al., 
2010). Earlier studies demonstrated that S. gordonii DL1 bound specifically to GPIIb but not 
GPIIIa of the GPIIbIIIa complex (Yajima et al., 2005). Collectively these results suggest that 
platelet adhesion is a mutlifactorial event where Hsa binds GPIbα and PadA binds 
GPIIb/IIIa and together they act synergistically to support platelet adhesion.  
Platelets are very sensitive to shear and some platelet-substrate interactions only manifest 
themselves upon exposure to shear. For example, under low shear conditions there is no 
interaction between platelets and vWf however under high shear conditions platelets roll 
along the vWf coated surface (Ruggeri, 2009). Perfusing platelets over immobilised S. 
sanguinis or S. gordonii in a parallel flow chamber under low shear (veneous shear), platelets 
interacted with a typical rolling behaviour followed by firm adhesion (Jakubovics et al., 
2005a; Plummer et al., 2005). This phenomena is highly characteristic of platelet rolling on 
damaged endothelium (Ruggeri, 2009). Rolling is mediated by platelet GPIbα where is the 
fast on-off rate of the receptor allows loss of interaction between GPIbα and the bacteria on 
one side of the platelet leading to the formation of another GPIbα-bacterial interaction on 
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the other side of the platelet. Deletion of the S. sanguinis GPIbα-binding protein SrpA or 
indeed the S. gordonii GPIbα-binding protein Hsa abolished the rolling behaviour, 
suggesting that these proteins form the initial attachment of platelets with the bacteria 
under physiological shear conditions. Soluble vWf exists in the plasma in a conformation 
that is not recognisable by platelet GPIbα. However at the site of injury, vWf binds to 
extracellular matrix proteins forming a thrombotic surface for the platelet. Typically 
platelets roll along immobilised vWf under high shear conditions. The high shear induces a 
conformational change in vWf making it recognisable to GPIbα. As S. gordonii Hsa and S. 
sanguis SrpA can support static platelet adhesion, or indeed mediate rolling of platelets 
under low shear conditions it suggests that Hsa and SrpA exist in a unique conformation 
that is recognisable by GPIbα, as their receptor conformation is not believed to be altered 
when subjected to shear. The process of rolling is to slow the platelet down from the high 
shear force experienced in the vasculature long enough to allow it firmly adhere to the 
bacteria. Firm adhesion is complete when platelet GPIIb/IIIa interacts with S. gordonii PadA.  
Once the platelets become firmly adhered to S. gordonii by engaging with either GPIbα or 
GPIIbIIIa, a signal is generated in the platelet that results in the platelet changing shape and 
spreading out on the bacterial surface. The function of platelet spreading is essential for the 
platelet to withstand the shear forces experienced in the vasculature. Platelet spreading is a 
particularly important in the development of thrombotic vegetations in infective endocarditis 
because the lesions around the lesion on the cardiac valve are often very turbulent. 
Therefore, platelets require the conversion from a discoid shape to a fully spread cell to 
withstand turbulent shear force. Keane et al, demonstrated that engagement of either GPIbα 
or GPIIbIIIa, the ITAM-bearing receptor, FcγRIIa and its downstream effectors syk and 
phospholipase Cγ2 became tyrosine phosphorylated which suggests that this pathway is 
essential for platelet spreading (Keane et al., 2010a). In addition tyrosine phosphorylation of 
the FcγRIIa resulted in platelet degranulation, a step critical for inducing and amplyfing 
platelet aggregation.  
Once platelets become firmly adhered and a signal is generated in the platelet it leads to 
platelet aggregation. Interestingly, while a mutant S. gordonii strain lacking expression of 
Hsa displayed reduced ability to support platelet adhesion, platelet aggregation remained 
unaffected. This observation suggests that different proteins expressed on the surface of S. 
gordonii mediate different interactions and subsequent responses in platelets. To address this 
Kerrigan et al used a proteomic approach to identify differentially expressed proteins on a 
strain of S. gordonii that induces platelet aggregation (S. gordonii strain DL1) versus one that 
does not (S. gordonii strain Blackburn). Cell wall proteins from both strains were removed 
from the cell wall using lysozyme. Recovered proteins were separated by poly-acrylamide 
gel electrophoresis and 2 bands corresponding to 172 kDa and 164 kDa were shown to be 
differentially expressed. Mass spectrometry identified these proteins as antigen I/II 
(Kerrigan et al., 2007). The antigen I/II family of proteins are probably the best characterised 
proteins on the surface of S. gordonii. Originally identified on Streptococcus mutans, antigen 
I/II have now been identified on almost all oral streptococci (Nobbs et al., 2007). In S. 
gordonii, antigen I/II have been designated SspA/B. These proteins are oligospecific 
adhesins which have been shown to bind to several ligands such as collagen type I (Heddle 
et al., 2003), β1 integrins (Nobbs et al., 2007), salivary agglutinin glycoprotein (Prakobphol et 
al., 2000) as well as other bacteria including P. gingivalis, Candida albicans and Actinomyces 
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naeslundii (Demuth et al., 2001; Egland et al., 2001; Jakubovics et al., 2005b). Deletion of 
SspA/B from S. gordonii DL1 failed to affect either platelet aggregation or platelet adhesion. 
However, deletion of SspA/B and Hsa together abolished platelet aggregation and reduced 
platelet adhesion by 50%, similar to the Hsa mutant alone (Kerrigan et al., 2007). Consistent 
with this over expression of SspA and SspB in the non-platelet reactive surrogate host 
Lactococcus lactis induced platelet aggregation but failed to support platelet adhesion. These 
results suggest that SspA/B and Hsa must act synergistically when binding to platelets to 
trigger aggregation and that they are not involved in supporting platelet adhesion. At 
present the receptor through which SspA/B binds to on the platelets is not current known.  
Bacteria Bacterial 
protein 
Platelet 
receptor 
Bridging 
protein 
Response 
S. sanguinis PAAP Not identified None Aggregation 
 Not identified FcγRIIa Antibody, 
fibrinogen & 
complement 
Aggregation 
 SrpA GPIbα None Adhesion / 
aggregation 
     
S. gordonii GspB GPIbα None Adhesion 
 Hsa GPIbα None Adhesion / 
aggregation 
 PadA GPIIbIIIa None Adhesion 
 SspA/B Not identified None Adhesion / 
Aggregation 
     
S. mitis PblA/B Not identified None Aggregation 
 Lysin GPIIbIIIa fibrinogen Aggregation 
     
S. mutans Rgp Not identified IgG Aggregation 
 PAc Not identified None Aggregation 
     
S. oralis  Not identified Not identified  None Adhesion / 
aggregation 
     
S. parasanguinis FimA Not identified None ? 
 Fap1 Not identified None Adhesion 
     
S. pneumoniae Not identified TLR2 None Aggregation 
Table 2. List of molecular interactions between Streptococci and platelets that contribute to 
Infective Endocarditis 
Streptococcus mitis has also been shown to interact with platelets although reports are 
conflicting. In 1990, Douglas et al, used several strains of S. mitis and found that none of 
these interacted with platelets. Ohkuni and colleagues suggested that S. mitis strain Nm-65 
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released a 66 kDa protein (S.mitis-derived human platelet aggregation factor, Sm-PAF) that 
induced platelet aggregation (Ohkuni et al., 1997). Characterisation of this secreted protein 
revealed that it was a toxin that lysed platelets rather than induced platelet aggregation. 
More recent work by Bensing et al, identified two distinct genetic loci of S. mitis strain SF100 
that contributes to platelet binding (Bensing et al., 2001a). The first locus encodes PblT. The 
mechanism through which it binds to platelets has not yet been explored. The second locus 
encodes two cell wall associated proteins; PblA is a 107 kDa protein and PblB which is a 121 
kDa protein (Bensing et al., 2001b). These proteins are unique as neither of the proteins 
expresses homology to any other bacterial adhesins described, however share similarities 
with structural components of bacteriophages (Mitchell et al., 2007). Bacteria often bind to 
oligosaccharides on host cells. For example S. gordonii GspB binds to α2-3-linked sialic acids 
on platelets and salivary mucins. Platelets treated with sialidases having different linkage 
specificities demonstrated that removal of α2-8-linked sialic acids resulted in a reduction in 
S. mitis SF100 binding. Gangliosides are glycosphingolipids rich in sialic acids and are found 
in abundance in lipid rafts in platelets (Marcus et al., 1972). S. mitis strains lacking the 
expression of PblA and PblB demonstrated significant decrease in platelet binding invitro as 
well as marked reduction in virulence in an animal model of infective endocarditis (Bensing 
et al., 2001b; Mitchell et al., 2007). More recent studies have demonstrated that S. mitis 
surface bound lysin can bind both free and platelet bound fibrinogen, through its interaction 
with the Aa and Bb chains of fibrinogen (Seo et al., 2010). Once S. mitis has bound fibrinogen 
this in turn can bind to the platelet fibrinogen receptor, GPIIbIIIa, initiating thrombus 
formation. 
Although early reports suggest Streptococcus oralis is capable of inducing platelet 
aggregation and supporting platelet adhesion the exact mechanism through which either of 
these occur is currently unknown.  
Streptococcus mutans strain Xc induces platelet aggregation by releasing extracts containing 
serotype-specific polysaccharides which are composed of rhamnose-glucose polymers. An 
isogenic mutant lacking synthesis the rhamnose-glucose polymers significantly reduced 
platelet aggregation (Chia et al., 2004). S. mutants failed to induce platelet aggregation in the 
absence of plasma proteins suggesting that a plasma protein possibly bridges the bacteria to 
the platelet. Subsequent studies identified that addition of serotype-specific IgG to plasma 
free platelets restored aggregation. The ability of rhamnose polymers toinduce platelet 
aggregation has been known for some time. For example, ristocetin is obtained from 
Amycolatopsis lurida and is well characterised for its ability to induce platelet 
agglutination. The mechanism of ristocetin induced agglutination of platelets involves vWf 
binding to platelet GPIbα. Cleavage of the rhamnose tetrasaccharide of ristocetin abolished 
its ability to induce platelet aggregation (Bardsley et al., 1998). Moreover, S. sanguinis 
expresses a platelet associated aggregating protein (PAAP) which is another rhamnose 
polymer which is thought to be involved in inducing platelet aggregation. Together these 
results suggest that rhamnose plays an important role in inducing platelet aggregation. 
Additional studies by Munro et al, demonstrated that an isogenic mutant of S. mutans strain 
V403 lacking the exopolysaccharides glucan and fructan had decreased infectivity in the rat 
model of endocarditis compared to the wild-type strain (Munro and Macrina, 1993). Protein 
antigen C (PAc) is a high molecular weight protein expressed by S. mutans that has been 
shown to interact with an unidentified platelet protein (Matsumoto-Nakano et al., 2009). 
Clinical strains that do not naturally express PAc failed to induce platelet aggregation. 
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Although the platelet receptor that recognises PAc was not identified, the authors 
demonstrated that increasing amounts of anti-PAc serum significantly reduced platelet 
aggregation, suggesting that antibody recognition may be a critical factor.  
Streptococcus parasanguinis expresses a 36kDa surface protein called FimA. A mutant 
defective on the expression of FimA from S. parasanguinis strain FW213 failed to have any 
effect on supporting platelet adhesion or inducing platelet aggregation however 
significantly reduced the extent of endocarditis in the rat model (Burnette-Curley et al., 
1995). Based on these observations the exact mechanism by which FimA functions as a 
virulence factor of endocarditis has yet to be determined, however it is possible that FimA 
plays a role in adherence to fibrin deposits associated with damaged heart valves. Fimbrae-
associated protein 1 (Fap1) is a highly glycosylated serine-rich glycoprotein which shares 
sequence and structural homology with SrpA of S. sanguinis, GspB of S. gordonii and SraP of 
S. aureus. SrpA of S. sanguinis and GspB of S. gordonii have both been shown to interact 
directly with platelet GPIbα to trigger platelet activation (Wu et al., 2007). To date no studies 
have demonstrated that Fap1 interacts with GPIbα or indeed with platelets directly.  
Early studies by Johnson et al, demonstrated that at low concentrations Streptococcus 
pneumoniae pneumolysin had little effect on platelets, however at higher concentrations 
platelets were lysed presumably by binding to the sterols present in the platelet plasma 
membrane and forming multimeric transmembrane pores (Johnson et al., 1981). The ability 
to form these pores may result in lysis of platelets. Lysis occurred in a time-dependent 
manner where greater than 50% of platelets were lysed. A more recent study demonstrated 
that a concentrated sample of supernatant from an overnight growth of S. pneumoniae that 
contained pneumolysin failed to induce human platelet aggregation, moreover a 
pneumolysin-negative strain of S. pneumoniae also induced platelet aggregation suggesting 
that pneumolysin is not involved in inducing platelet aggregation (Keane et al., 2010b). In 
this report the authors demonstrated that S. pneumoniae binds to platelet toll like receptor 2 
(TLR2), a pattern recognition receptor which triggered the PI3kinase/RAP1 pathway which 
leads to activation of the fibrinogen receptor GPIIbIIIa.  
8. Platelet-bacterial interactions: Non staphylococcal, non streptococcal 
There is no doubt Staphylococcus and Streptococcus species make up the majority of cases 
of infective endocarditis, however other opportunistic pathogens, while rare, may also play 
a role (Table 3). For example recent work by Shannon et al. demonstrated that clinical 
isolates of Enterococcus faecalis induced platelet aggregation. The ability of the E. faecalis to 
induce platelet aggregation was dependent on IgG (Rasmussen et al., 2010). Helicobacter 
pylori has also been shown to interact with platelets. When in plasma it binds 
vonWillebrand factor, which in turn enables it to interact with GPIbα and trigger platelet 
aggregation. This is a unique interaction as soluble vonWillebrand factor cannot interact 
with platelet GPIbα. The H. pylori protein that binds vonWillebrand factor is currently not 
identified (Byrne et al., 2003; Corcoran et al., 2007). Porphyromonas ginigvalis secretes a 
protease called gingipains that acts directly on platelet protease activated receptors 
(Lourbakos et al., 2001). Naito and colleagues also deomstrated that P. ginigvalis expresses 
a protein called Hgp44 which also induces platelet aggregation. Although the platelet 
receptor has not been definitively identified antibodies against GPIbα abolish the 
interaction (Naito et al., 2006). Finally, Escherichia coli secretes shiga-like toxin which binds  
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to the glycosphingolipid receptors on the surface of the platelet and triggers platelet 
activation (Cooling et al., 1998), however other groups failed to see the interaction in vivo 
(Viisoreanu et al., 2000). One explanation for these contradictory results is that in vivo the 
actions of Shiga toxins are complex and many of its actions on platelets are indirect being 
mediated through effects on other cells such as monocytes (Guessous et al., 2005) and 
endothelial cells (Motto et al., 2005). 
Bacteria Bacterial 
protein 
Platelet 
receptor 
Bridging 
protein 
Response  
     
Enterococcus 
faecalis 
Not identified FcgRIIa IgG Aggregation 
     
Helicobacter pylori Not identified GPIbα vonWillebrand 
Factor 
Aggregation 
 
     
Porphyromonas 
gingivalis 
RgpA/B PAR1 & PAR4 None Aggregation 
 Hgp44 GPIbα Not identified Aggregation 
     
Escherichia coli Shiga-like 
toxin 
Sphingolipids None Aggregation  
Table 3. List of molecular interactions between non staphylococcal non streptococcal 
microorganisms and platelets that may contribute to Infective Endocarditis 
9. Current and novel treatment options for infective endocarditis 
As infective endocarditis is primarily a bacteria infection, often associated with dental and 
other medical procedures, prophylactic antibiotic treatment was considered to be normal 
practice. However, more recently the American Heart Association (AHA) and American 
College of Cardiology (ACC) released a guidance document on infective endocarditis that 
significantly changed routine practice (Nishimura et al., 2008). In particular they no longer 
recommend the prophylactic use of antibiotics for dental or other procedures except for a 
small group of high-risk patients. This was primarily due to the fact that the risks associated 
with prophylaxis outweigh the benefits. The review panel felt that the biggest risk for IE is 
not dental or other procedures but rather bleeding from gums due to poor oral hygiene. 
Thus, so few cases of IE will be prevented by antibiotic prophylaxis during medical 
procedures but there will be an increase in antibiotic resistance that the there is little benefit 
to prophylaxis. They felt that improved oral hygiene would be more effective at preventing 
the occurrence of IE. The exception was for very high-risk patients, which are basically 
patients with prosthetic valves or those with a history of IE.  
With the increase in antibiotic-resistant strains of pathogenic bacteria researchers have been 
looking at new strategies to target bacteria. One such approach is to target the host response 
to the pathogen (Clatworthy et al., 2007). IE is very amenable to this strategy as it basically 
arises from an ineffective host response to the infection. If the platelet aggregation response 
can be prevented there would be no thrombus formation. 
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The obvious strategy would be to use an anti-platelet agent to prevent the thrombus 
formation. Aspirin is the most widely used anti-platelet agent and acts to inhibit 
cyclooxygenase but may not be effective in preventing IE (Chan et al., 2003). While aspirin 
effectively inhibits COX some bacteria can activate platelets in a COX-independent manner. 
As it is not known prior to the procedure which bacteria are likely to be involved aspirin 
would not be sufficient. A more effective strategy would be to use a P2Y12 antagonist such as 
clopidogrel. However, its very effectiveness makes it unlikely to be used. The inhibition of 
platelet function by clopidogrel and other anti-platelet agents cause bleeding and it is 
unlikely that dentists would be happy to perform extractions and other such procedures 
when the patient is likely to experience very heavy bleeding. Certainly surgeons will not 
operate on a patient on clopidogrel and they typically require a reversal of the inhibition 
before they will consider surgery. 
Targeting the bacteria is an approach that is attractive, as it would not interfere with platelet 
function. However, as we have seen choosing a target is difficult as every species of bacteria 
interact differently with platelets and even different strains of the same species can interact 
differently (Fitzgerald et al., 2006a). There is also the problem that bacteria such as S. aureus 
have multiple interactions with platelets and it is not clear which one if any is the critical 
one during IE. Certainly if it was possible to identify a single bacterial protein that was 
conserved across many pathogenic strains and was found to be critical in the interaction 
with platelets it would be possible to produce a vaccine against it (Broughan et al., 2011).  
Despite the limitations associated with the use of anti-platelet agents platelets are still a 
promising target for any potential new drug. This is because so far there are only a few 
platelet receptors implicated in the response to bacteria primarily GPIIb/IIIa and GPIbα. 
GPIIb/IIIa plays an important role in S. aureus-and S. gordonii mediated platelet aggregation 
but as the fibrinogen receptor it also plays a critical role in platelet aggregation. Because of 
this important role in platelet function a number of inhibitors of this receptor have been 
developed. Although only for intravenous use these drugs have been very effective anti-
platelet agents (Curtin, 2004). However, they are very potent in their inhibition and will 
cause a profound inhibition of platelet function along with a prolongation of bleeding time 
that will not be suitable for prophylaxis during procedures such as dental manipulations.  
A second platelet receptor that is important in the platelet response to bacteria is GPIbα, 
which is the von Willebrand factor receptor. GPIbα is very important in platelet adhesion 
under shear stress and is a very attractive target in cardiovascular disease. However, despite 
the efforts of many researchers to discover GPIbα inhibitors none have yet made it to the 
market (Vanhoorelbeke et al., 2007). 
FcγRIIa has been shown to mediate platelet activation by many different bacteria including 
Staphylococci and Streptococci. It typically acts in conjunction with GPIbα, GPIIb/IIIa or the 
complement receptor. Unlike receptors such as GPIbα and GPIIb/IIIa FcγRIIa is not 
involved in thrombosis as its role are primarily involved in the immune function of 
platelets. Thus, antagonists of FcγRIIa will have little impact on platelet function and will 
not cause bleeding problems making it an ideal target for prophylactic therapy for IE. 
The interaction between platelets and bacteria is the key element of infective endocarditis. 
While there are many different bacterial proteins that can bind to platelets there are only a 
few potential receptors on the platelet for these proteins. This makes the platelet a good 
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target for novel strategies to inhibit this interaction. While there is always a risk of causing 
bleeding problems with anti-platelet agents FcγRIIa has been found to be the critical 
receptor on platelets for the interaction with bacteria. As this receptor is associated with the 
innate immune functions of platelets rather than with its role in thrombosis targeting 
FcγRIIa will have minimal effects on the role of platelets in thrombosis. This strategy would 
be in line with the recent guidance document on infective endocarditis from AHA/ACC. 
Prophylactic use of an FcγRIIa antagonist during medical procedures with no risk of 
developing resistance. Antibiotic therapy could then be reserved for cases of sepsis or 
confirmed infective endocarditis. 
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